Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.
Open accessThe DOI matches its Crossref record.
Abstract
Transgenic mice overexpressing the human growth hormone gene develop mammary carcinomas. Since human growth hormone gene can activate both the growth hormone receptor (GHR) and the prolactin (PRL) receptor (PRLR), it is not clear which receptor system is responsible for the malignant transformation. To clarify the receptor specificity, we created transgenic mice with two different genes: (a) transgenic mice overexpressing the bovine growth hormone (bGH) gene having high levels of bGH only activating the GHR and also high serum levels of IGF-I; and (b) transgenic mice overexpressing the rat PRL (rPRL) gene that have elevated levels of PRL (one line 150 ng/ml and one line 13 ng/ml) only binding to the PRLR and with normal IGF-I levels. When analyzed histologically, all of the PRL transgenic female mice developed mammary carcinomas at 11-15 mo of age. Only normal mammary tissue was observed among the bGH transgenic animals and the controls. Cell lines established from a tumor produced rPRL and expressed PRLR. In organ culture experiments, an auto/paracrine effect of rPRL was demonstrated. In conclusion, activation of the PRLR is sufficient for induction of mammary carcinomas in mice, while activation of the GHR is not sufficient for mammary tumor formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0022 · Cited by 1,309
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
The Role of Prolactin in Mammary Carcinoma
Clevenger, C. V., Furth, P. A., Hankinson, S. E., & Schuler, L. A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0036 · Cited by 545
What Can We Learn from Rodents about Prolactin in Humans?
Ben-Jonathan, N., LaPensee, C. R., & LaPensee, E. W. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0017 · Cited by 523
Prolactin: The New Biology of an Old Hormone
Goffin, V., Binart, N., Touraine, P., & Kelly, P. A. (2002) · Annual Review of Physiology · doi:10.1146/annurev.physiol.64.081501.131049 · Cited by 416
Growth hormone, the insulin-like growth factor axis, insulin and cancer risk
Clayton, P. E., Banerjee, I., Murray, P. G., & Renehan, A. G. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.171 · Cited by 364
Tworoger, S. S., Sluss, P., & Hankinson, S. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3369 · Cited by 246
Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists
Goffin, V., Bernichtein, S., Touraine, P., & Kelly, P. A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0016 · Cited by 199
“The impact of autocrine PRL on mammary tumorigenesis may even be predominant over that of circulating PRL, because the various strains of transgenic mice overexpressing systemic PRL develop mammary tumors with similar characteristics, irrespective of their circulating levels of PRL (38).”
InfluentialProlactin as an autocrine/paracrine growth factor in human cancer
Ben-Jonathan, N., Liby, K., McFarland, M., & Zinger, M. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(02)00603-3 · Cited by 177
Kleinberg, D. L., Wood, T. L., Furth, P. A., & Lee, A. V. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0022 · Cited by 161
“(152) found that diffusely expressed mammary gland metallothionein enhancer promoter regulated hGH was able to bind the prolactin receptor and suggest that downstream gene activation through this receptor mediates the increase in mammary tumorigenesis.”
Background
Metadata
- Authors
- Wennbo, H., Gebre-Medhin, M., Gritli-Linde, A., Ohlsson, C., Isaksson, O. G., & Törnell, J.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-12-01
- Volume
- 100
- Issue
- 11
- Pages
- 2744-2751
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1969890794
- Cited by
- 207
- References
- 0
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.